PD-1/PD-L1抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌中的应用价值

Value of PD-1/PD-L1 Inhibitors Combined with Bevacizumab in Advanced Triple-negative Breast Cancer

目的探究程序性死亡受体1(PD-1)/程序性死亡受体-配体1(PD-L1)抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌(TNBC)中的应用效果。方法选择本院2020年1月~2021年12月诊治的102例晚期TNBC患者,按治疗方式不同将其设为47例对照组(PD-1/PD-L1抑制剂治疗)与55例研究组(PD-1/PD-L1抑制剂联合贝伐珠单抗治疗)。比较两组疗效、不良反应及预后情况。结果研究组总体客观缓解率36.36%,比对照组17.02%高(P<0.05)。两组不良反应总发生率对比无差异(P>0.05)。研究组无进展生存期比对照组高(P<0.05);两组复发率对比无差异(P>0.05)。结论PD-1/PD-L1抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌中的疗效确切,可改善患者短期预后,且安全性可控,临床应用价值较高。

Objective To investigate the efficacy of programmed death receptor-1(PD-1)/programmed death receptor-ligand 1(PD-L1)inhibitors combined with bevacizumab in advanced triple-negative breast cancer(TNBC).Methods A total of 102 patients with advanced TNBC diagnosed and treated in our hospital from January 2020 to December 2021 were selected and divided into 47 control group(PD-1/PD-L1 inhibitor treatment)and 55 study group(PD-1/PD-L1 inhibitor combined with bevacizumab treatment)according to different treatment methods.The efficacy,adverse reactions and prognosis of the two groups were compared.Results The overall objective remission rate of the study group was 36.36%,higher than that of the control group 17.02%(P<0.05).There was no difference in the total incidence of adverse reactions between the two groups(P>0.05).The progression-free survival of the study group was higher than that of the control group(P<0.05).There was no difference in recurrence rate between the two groups(P>0.05).Conclusion PD-1/PD-L1 inhibitor combined with bevacizumab is effective and can improve the short-term prognosis of patients with advanced triple-negative breast cancer,with controllable safety and high clinical application value.